Auxo Firm Directory · Independent Research Profile

Avista Capital Partners

Avista Capital Partners focuses on healthcare companies, including outsourced pharma and medtech services, consumer healthcare, medical devices and medtech, pharmaceuticals, distribution and diagnostics, and healthcare technology. It describes a proactive, hands-on ownership approach, flexible deal structures, and a focus on mid-sized companies with strong management teams, stable cash flows, and robust growth prospects.

Key takeaway

Avista Capital Partners publicly describes a healthcare-focused investment strategy.

Avista Healthcare Partners VI targets high-growth middle-market product and technology healthcare businesses in North America and Europe. Avista’s materials identify flexible capital solutions, prudent leverage, operational support, acquisitions, and management partnerships as elements of its approach. The Approach page does not state a universal current equity-check range, minimum investment size, or standard ownership percentage.[1][2][3][5][6]

What does Avista Capital Partners invest in?

Avista was founded in 2005 as a spin-out from DLJ Merchant Banking. Its current official web presence is branded Avista Healthcare and identifies Avista Capital Holdings, LP. Avista invests in healthcare companies and provides flexible capital solutions, operational insight, regulatory insight, and business-management support to portfolio-company management teams.[1][2]

Avista describes a proactive, hands-on approach that supports organic growth, accretive acquisitions, and increased operational efficiencies. It also describes creative deal structures and a prudent approach to leverage.

For owners, this means the firm’s stated approach combines capital with operational, regulatory, and business-management support. Specific structure, leverage terms, and ownership position should be clarified for a prospective transaction.[2]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Published size criteriaPublicly stated range
Lower published point$10BILLION
Upper published point$1.5BILLION

Published criteria: Avista focuses on mid-sized companies with strong management teams, stable cash flows, and robust growth prospects. Avista states that it has invested over $10 billion in 50 healthcare companies and supported more than 100 add-on acquisitions. Avista Healthcare Partners VI closed at $1.5 billion.[1][2][3]

What should a business owner evaluate before considering a transaction with Avista Capital Partners?

An owner evaluating Avista should assess how the company’s healthcare activities align with Avista’s stated sector focus and criteria, including management strength, stable cash flows, and growth prospects. The owner should also clarify control expectations, rollover or management reinvestment, governance, leverage, potential add-on activity, and the intended role of existing management. The Approach page does not state a universal current equity-check range, minimum investment size, or standard ownership percentage, so those points should be addressed directly for the relevant transaction.[1][2]

01

What is Avista’s current equity-check range for new platform investments

The Approach page does not state a universal current equity-check range or minimum investment size. The equity-check range and enterprise-value range should be clarified directly for a prospective transaction.[2]
02

Does Avista seek control, joint control, or influential minority positions for the relevant transaction

Avista’s Cosette announcement describes joint control with Hamilton Lane, while the Approach page does not state a standard ownership percentage. The ownership position for a new transaction should therefore be clarified.[2][4]
03

What percentage of seller rollover or management reinvestment is expected

The Terrats announcement states that the founders and Miura reinvested. The expected percentage for a prospective transaction should be clarified directly.[2][5]

What companies does Avista Capital Partners target?

Avista focuses on mid-sized companies with strong management teams, stable cash flows, and robust growth prospects. Avista Healthcare Partners VI targets high-growth middle-market product and technology healthcare businesses.

Avista states that it has invested over $10 billion in 50 healthcare companies and supported more than 100 add-on acquisitions. Avista Healthcare Partners VI closed at $1.5 billion, exceeding its $1.25 billion target.[1][2][3]

Avista focuses on outsourced pharma and medtech services, consumer healthcare, medical devices and medtech, specialty and generic pharmaceuticals, distribution and diagnostics, and healthcare technology.[2]

Avista Healthcare Partners VI targets high-growth middle-market product and technology healthcare businesses in North America and Europe. This Fund VI mandate describes the fund’s focus rather than a universal geographic restriction for every Avista transaction.[3]

Avista describes support for accretive acquisitions and states that it has supported more than 100 add-on acquisitions. Its public transaction record also includes acquisitions and ownership partnerships involving healthcare businesses.

An owner considering a transaction should clarify whether the opportunity would be evaluated as a new platform investment or in connection with an existing portfolio company, and how any add-on strategy would apply.[1][2][4][5][6][7]

Public announcements identify Cosette Pharmaceuticals, Terrats Medical, Taconic Biosciences, and WellSpring Consumer Healthcare through partnership and acquisition announcements.[4][5][6][7]

  • Cosette Pharmaceuticals: On July 17, 2024, Avista announced that funds managed by Hamilton Lane acquired a significant equity interest in Cosette Pharmaceuticals from Avista and its co-investors, with Avista and Hamilton Lane jointly controlling Cosette going forward.
  • Terrats Medical: On February 16, 2024, Avista announced its acquisition of Terrats Medical from Miura Partners; Terrats’ founders and Miura reinvested in the company.
  • Taconic Biosciences: On November 1, 2022, Avista announced its acquisition of Taconic Biosciences from H.I.G. Capital.
  • WellSpring Consumer Healthcare: On August 23, 2022, Avista announced completion of its acquisition of WellSpring Consumer Healthcare from Audax Private Equity.
[4][5][6][7]

What is not clear from Avista Capital Partners's public investment criteria?

The Terrats Medical announcement states that the acquisition was announced but does not disclose transaction terms. The Taconic Biosciences announcement states that transaction terms were not disclosed.

The Approach page does not state a universal current equity-check range, minimum investment size, or standard ownership percentage. The About page identifies Avista Capital Holdings, LP and describes investment-vehicle offering procedures but does not establish a firm-level SEC, FINRA, or other regulatory registration status for Avista Capital Partners or Avista Capital Holdings, LP.[1][2][5][6]

Questions to ask when evaluating Avista Capital Partners as a buyer or investment partner

What is Avista’s current equity-check range for new platform investments?
The Approach page does not state a universal current equity-check range or minimum investment size. The equity-check range and enterprise-value range should be clarified directly for a prospective transaction.[2]
Does Avista seek control, joint control, or influential minority positions for the relevant transaction?
Avista’s Cosette announcement describes joint control with Hamilton Lane, while the Approach page does not state a standard ownership percentage. The ownership position for a new transaction should therefore be clarified.[2][4]
What percentage of seller rollover or management reinvestment is expected?
The Terrats announcement states that the founders and Miura reinvested. The expected percentage for a prospective transaction should be clarified directly.[2][5]
How does Avista structure leverage and add-on acquisition funding?
Avista describes a prudent approach to leverage and support for accretive acquisitions. Transaction-specific leverage and add-on funding terms should be clarified.[1][2]
What is the expected ownership horizon and exit approach for a new investment?
An expected ownership horizon and exit approach for a new investment should be clarified directly.[2][4][5][6][7]
Which operating, regulatory, or business-management resources would support the company?
Avista states that it provides operational insight, regulatory insight, and business-management support to portfolio-company management teams. The specific resources for a prospective company should be clarified.[2]
What transaction terms, fees, indemnities, and governance rights would apply?
The Terrats and Taconic announcements do not disclose transaction terms, and the Approach page does not state a standard ownership percentage. Transaction-specific economics, indemnities, governance rights, and fees should be addressed directly.[2][5][6]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Geography / market coverage
  4. Transaction / portfolio evidence
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.